Notably, this Denosumab-dependent survival advantage occurred in lung cancer patients irrespective of visceral metastasis, hinting that the underlying effects of RANKL/RANK blockade, in addition to those targeting the bone, are involved (100). The gene discussed is TNFRSF11A; the disease is lung carcinoma.